Structural studies of human kidney heparan sulphate and its role in lupus nephritis.

by Christopher Ross Simpson

Publisher: University of Manchester in Manchester

Written in English
Published: Pages: 272 Downloads: 877
Share This

Edition Notes

Thesis (Ph.D.), University of Manchester, School of Biological Sciences.

ContributionsUniversity of Manchester. School of Biological Sciences.
The Physical Object
Number of Pages272
ID Numbers
Open LibraryOL22832368M

  Systemic lupus erythematosus is a prototypic autoimmune disease characterized by autoantibody production and immune complex formation/deposition in target organs such as the kidney. Resultant local inflammation then leads to organ damage. Nephritis, a major cause of morbidity and mortality in patients with lupus, occurs in approximately 50% of lupus by: Lupus is no longer an unknown chameleon of medicine. Significant progress has been made on unraveling the pathogenesis of lupus and lupus nephritis, and how to treat the disease. Here we provide an update on the pathophysiology of lupus and its related kidney disease, consider areas of controversy in disease management, and discuss the unmet needs of lupus nephritis and Cited by: Learn term:nephrology = study of the kidney and its diseases with free interactive flashcards. Choose from different sets of term:nephrology = study of the kidney and its diseases flashcards on Quizlet. Lupus Nephritis refers a kidney disorder, in which the filters (glomeruli) of kidneys are inflamed. It is a complication of systemic lupus erythematosus (SLE). SLE is an autoimmune disease which may typically cause harm to the skin, joints, kidneys, and brain.

In our series, relapsing lupus nephritis was found only in one case (2%). The recurrence rate of lupus nephritis was reported initially to be around 1–4% [32, 33]. However, immunofluorescence and electron microscopy studies performed in renal biopsies of SLE transplanted patients detected a rate of recurrent lupus nephritis of 30% [19, 34, 35].Cited by:   Background/Purpose: Kidney biopsy remains the gold standard for diagnosis and staging of Lupus Nephritis (LN). Although kidney biopsies are commonly performed in the clinical setting, they carry morbidity. Identification of reliable biomarkers in the blood that correlate with pathological changes in the kidney of LN patients may allow LN diagnosis and staging with . Background/Purpose: Most published studies that have measured activity in patients with lupus nephritis suggest the disease is relatively quiescent after renal failure. Purpose: To analyze retrospectively the activity index of 32 patients in end-renal stage disease (ESRD) from a cohort of patients with lupus nephritis during dialysis and/or post renal transplant. Using a manmade version of a human antibody to directly deliver a drug that inhibits a powerful driver of inflammation, can reverse a disease course that often leads to kidney failure and dialysis.

To address the question of short-term response criteria and long-term kidney function, post hoc analyses of the Euro-Lupus Nephritis and MAINTAIN trials were done to determine whether SCr, proteinuria, or hematuria within the first year of treatment predicted an SCr Cited by: T1 - Mechanisms of progression of renal damage in lupus nephritis. T2 - Pathogenesis of renal scarring. AU - Grande, J. P. PY - /12/1. Y1 - /12/1. N2 - Lupus nephritis results from an acute inflammatory and immunological response to renal immune complex by: Lupus nephritis is a frequent manifestation of systemic lupus erythematous. Lupus nephritis usually presents with abnormal urinalysis, proteinuria, and/or renal insufficiency. We report a case of a year-old woman who underwent partial nephrectomy for a fortuitously discovered solid enhancing left kidney mass. No neoplastic cells were found in the biopsy specimen; however, Author: Remi Goupil, Annie-Claire Nadeau-Fredette, Virginie Royal, Alexandre Dugas, Jean-Philippe Lafrance. In many cases, treatment is effective in completely or partially controlling lupus nephritis, resulting in few, if any, further complications. However, even with treatment, 10 to 30 percent of people with lupus nephritis develop kidney failure. A normal result is to mg/dL for men and to mg/dL for women.

Structural studies of human kidney heparan sulphate and its role in lupus nephritis. by Christopher Ross Simpson Download PDF EPUB FB2

Chemokine production in the glomerulus is an early event during experimental lupus nephritis and precedes cellular infiltration, proteinuria, and kidney damage. MCP-1 is one of the most studied chemokines in human and experimental lupus nephritis (90, 91).

Renal involvement in systemic lupus erythematosus (SLE) affects the disease outcome. In order to advance the diagnosis and the initiation of therapy, non-invasive diagnostic techniques are required.

In this study, urinary glycosaminoglycans (GAG) and heparan sulphate (HS) were measured in 26 patients with biopsy-proven lupus nephritis and compared to 16 Cited by: 5. The Urinary Excretion of Glycosaminoglycans and Heparan Sulphate in Lupus Nephritis Article (PDF Available) in Clinical Rheumatology 21(4) September with.

Increased excretions of glycosaminoglycans and heparan sulfate in lupus nephritis and rheumatoid arthritis. Since the human kidney is a target tissue for inflammation and autoimmune disorders. pathogenesis of lupus and lupus nephritis, and how to treat the disease. Here we provide an update on the pathophysiology of lupus and its related kidney disease, consider areas of controversy in disease management, and discuss the unmet needs of lupus nephritis and how to address these needs.

We focus on rethinking how. Lupus nephritis disease burden. SLE is a complex and potentially life-threatening autoimmune disease.

Kidney involvement, which affects the majority of patients, remains the most significant cause of morbid and mortal complications [3,4].The incidence of ESKD and the overall mortality among patients with LN have not improved in populations studied in London, Cited by: Curr Treat Options in Rheum () – DOI /sx Lupus (S Manzi, Section Editor) Management of Lupus Nephritis Fernanda Payan Schober, MDAuthor: Fernanda Payan Schober, Mary Anne Dooley.

Immune complex accumulation in the kidney is the hallmark of lupus nephritis and triggers a series of events that result in kidney inflammation and injury.

Cytotoxic agents and corticosteroids are standard of care for lupus nephritis treatment, but are associated with considerable morbidity and suboptimal outcomes.

Recently, there has been interest in using novel biologic agents Cited by: Membranous lupus nephritis (MLN) has a favorable prognosis compared to proliferative lupus nephritis (PLN) or combined MLN/PLN, although a significant proportion of cases will progress to end-stage kidney disease.

There is considerable morbidity associated with thrombotic complications and treatment. Nondirected care includes renin-angiotensin-aldosterone system Cited by: 6. Click here to read the release. As we get older, we start to lose some of our kidney function.

Lupus Nephritis. Lupus Nephritis (LN) is the disease of the kidneys due to lupus. This occurs when lupus autoantibodies deposit in the kidneys and cause inflammation. About % of lupus patients will develop LN within the first six months to three years of being diagnosed with SLE.

Lupus nephritis (LN) is a feature of systemic lupus erythematosus (SLE) and is linked to poor clinical outcome in patients.

Markers of SLE activity, including serum complement (C)3, C4 and anti-double-stranded (ds)DNA antibody, are conventional biomarkers for assessing disease severity [ 17 ], but are insufficient for predicting the Cited by: Lupus nephritis is a severe form of systemic lupus erythematosus (SLE) with active disease in the kidneys.

SLE is a complex disease in which the body's own immune system attacks some of the body parts: the skin, the joints, the kidneys, the nervous system, the heart, the lungs and the. INTRODUCTION.

Despite advancements in the management of lupus nephritis in the past few decades, the cumulative risk of progression to end-stage renal disease (ESRD) in 10 years time still ranges from 10 to 62% [].Factors affecting the prognosis of lupus nephritis include African or Hispanic ethnicity, renal histology showing high activity in a background of chronic Cited by:   Immune abnormalities in lupus nephritis.

The role of immune system abnormalities in SLE development and progression is well established, and several such abnormalities are associated with renal involvement, including antiphospholipid, anti-DNA and anti-Smith antibodies as well as low levels of C3 and C4.

Lupus Nephritis is an inflammation of the kidney that is caused by systemic lupus erythematosus, or SLE. It is just one complication of to trigger major health problems, lupus can set off inflammation and can cause damage in the heart, lungs, blood vessels, brain, joints, skin, kidneys, and other parts of the body.

Nephritis refers to the inflammation of blood filters in kidneys. Once the filters are impaired, they will not able to excrete the. metabolic products and keep the nutrients in body. The causes of nephritis in children and adults may have a mild difference.

Streptococcus bacteria infection is a common cause of nephritis, especially in children. Recent knowledge on renal inflammation in lupus nephritis (a) Role of resident kidney cells The mesangium is the site for anti-dsDNA antibody-containing immune complex deposition in the glomerulus in less severe forms of LN, and mesangial immune deposits are always present in severe nephritis.

The treatment of lupus nephritis has changed significantly over the past decade in large part because of data from well-conducted randomized clinical trials. The concept of two phases of therapy—induction and maintenance—is widely accepted.

The histopathologic classification of lupus nephritis continues to. The Prognosis of Different Types of Lupus Nephritis In a few decades ago, it is easy for Lupus Nephritis to turn into end-stage kidney failure as there was no effective management for Lupus Nephritis.

However, nowadays, with comprehensive management, Lupus Nephritis can be controlled well and patients’ prognosis can be improved greatly. Objective. This observational study was a retrospective analysis of prospectively collected Hopkins Lupus Cohort data to compare longterm renal survival in patients with lupus nephritis (LN) who achieved complete (CR), partial (PR), or no remission following standard-of-care LN induction therapy.

Methods. Eligible patients with biopsy-proven LN (revised American Cited by: 8. Inflammation inhibitor delivered directly to kidneys reverses course of destructive nephritis J Using a manmade version of a human antibody to directly deliver a drug that inhibits a powerful driver of inflammation, can reverse a disease course that often leads to kidney failure and dialysis, investigators report.

What Is the Life Expectancy of Lupus Nephritis Stage 4 Lupus Nephritis is one of the the most serious complications of lupus.

Without timely treatment to stabilize it, your life may be threatened. Today let’s have a. The Role of Uric Acid in Acute Kidney Injury, A. Ahsan Ejaz, MD (S) we have expertise in the care of lupus patients who are pregnant. This is one of only a few truly multispecialty clinics for Lupus Nephritis in the country and we are privileged to care for patients with Lupus Nephritis from across the state of Florida.

Is There Any Natural Treatment to Lupus Nephritis Lupus nephritis refers to a medical condition in which the kidney is damaged by the abnormal immune system. Usually, the patients will take steroids or dialysis, even transplant.

Owing to various account, more and more lupus nephritis are eager to seek out a natural treatment. title = "Lupus-like nephritis in an HIV-positive patient: Report of a case and review of the literature", abstract = "The most common manifestation of HIV/AIDS in the kidney is the collapsing variant of focal segmental glomerular sclerosis, HIV-associated nephropathy (HIVAN).Cited by: Objective To evaluate candidate biomarkers to predict future renal function decline (RFD) in children and adults with lupus nephritis (LN).

Methods At the time of enrollment into prospective observational LN cohort studies liver-type fatty acid binding protein (LFABP), albumin, monocyte chemoattractant protein-1 (MCP-1), uromodulin, transferrin, and hepcidin were measured in Cited by:   Lupus nephritis is a common and severe manifestation of systemic lupus erythematosus, and an important cause of both acute kidney injury and end-stage renal disease.

Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE), usually arises within 5 years of diagnosis; however, renal failure rarely occurs before American College of Rheumatology criteria for classification are met.

Lupus nephritis is histologically evident in most patients with SLE, even those without cl. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with various clinical manifestations.

The hallmark of SLE is the presence of antibodies against nuclear constituents, such as double-stranded (ds)DNA, histones, and nucleosomes. Local deposition of antinuclear antibodies in complex with nuclear autoantigens induces serious inflammatory conditions that.

Conventional lupus nephritis (LN) treatment based on cyclophosphamide, steroids and, recently, mycophenolatemofetil has improved the outcome of the disease over the last 50 years, although failure.The role of the nephrologist in the treatment of lupus nephritis Charles J Diskin 1 Nature Clinical Practice Nephrology volume 3, page E1 () Cite this article.

A new case study entitled “Acute kidney injury associated with minimal change disease in systemic lupus erythematosus: a case report” describes a rare case of a patient with Systemic lupus erythematosus and acute kidney injury associated with minimal change study was published in the Journal of Medical Case Reports.

Systemic lupus .